GFAP versus S100B in serum after traumatic brain injury: Relationship to brain damage and outcome

被引:221
|
作者
Pelinka, LE
Kroepfl, A
Leixnering, M
Buchinger, W
Raabe, A
Redl, H
机构
[1] Ludwig Boltzmann Inst Expt & Clin Traumatol, A-1200 Vienna, Austria
[2] Austrian Workers Compensat Board, Res Unit, AUVA, Vienna, Austria
[3] AUVA, Trauma Hosp Linz, Linz, Austria
[4] Waldviertel Clin, Dept Traumatol, Horn, Austria
[5] Goethe Univ Frankfurt, Dept Neurosurg, Neuroctr, D-6000 Frankfurt, Germany
关键词
computerized tomography; GFAP; intracranial pressure; neuromarkers; perfusion pressure; S100B protein;
D O I
10.1089/0897715042441846
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Research indicates that glial fibrillary acidic protein (GFAP), part of the astroglial skeleton, could be a marker of traumatic brain injury (TBI). S100B, an astroglial protein, is an acknowledged marker of TBI. Our goal was to analyze the relationship of GFAP/S100B to brain damage and outcome, and to compare the accuracy of GFAP/S100B for prediction of mortality after TBI. Our prospective study included 92 patients admitted <12 h after TBI (median injury severity score 25, median Glasgow Coma Scale 6). TBI was verfied by computerized tomography. GFAP/S100B were measured immunoluminometrically at admission and daily in the intensive care unit (average 10 days, range 1-21 days). We compared GFAP/S100B in non-survivors versus survivors, accuracy for mortality prediction according to receiver operated characteristic curve analysis, correlation between GFAP and S100B, relationship of GFAP/S100B to computerized tomography, cerebral perfusion pressure (CPP), mean arterial pressure (MAP) and 3-month Glasgow Outcome Score (GOS). GFAP (p < 0.005) and S100B (p < 0.0005) were higher in non-survivors than survivors. Both GFAP and S100B were accurate for mortality prediction (area under curve 0.84 versus 0.78 at <12 h after TBI). GFAP and S100B release correlated better later than 36 h after TBI (r = 0.75) than earlier (r = 0.58). GFAP was lower in focal lesions of <25 mL than in shifts of >0.5 cm (P < 0.0005) and non-evacuated mass lesions of >25 mL (p < 0.005). S100B was lower in focal lesions of <25 mL than in non-evacuated mass lesions (p < 0.0005) and lower in swelling than in shifts of >0.5 cm (p < 0.005). GFAP and S100B were lower in ICP < 25 than ICP greater than or equal to 25 (p < 0.0005), in CPP greater than or equal to 60 than CPP < 60 (p < 0.0005), in MAP > 70 than MAP:5 70 nun Hg, and in GOS 4-5 than GOS 1 (p < 0.0005). Both measurement of GFAP and S100B is a useful non-invasive means of identifying brain damage with some differences based on the pattern of TBI and accompanying multiple trauma and/or shock.
引用
收藏
页码:1553 / 1561
页数:9
相关论文
共 50 条
  • [31] S100B, Actor and Biomarker of Mild Traumatic Brain Injury
    Oris, Charlotte
    Kahouadji, Samy
    Durif, Julie
    Bouvier, Damien
    Sapin, Vincent
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (07)
  • [32] S100B Protein May Detect Brain Death Development after Severe Traumatic Brain Injury
    Egea-Guerrero, Juan J.
    Murillo-Cabezas, Francisco
    Gordillo-Escobar, Elena
    Rodriguez-Rodriguez, Ana
    Enamorado-Enamorado, Judy
    Revuelto-Rey, Jaume
    Pacheco-Sanchez, Maria
    Leon-Justel, Antonio
    Dominguez-Roldan, Jose M.
    Vilches-Arenas, Angel
    JOURNAL OF NEUROTRAUMA, 2013, 30 (20) : 1762 - 1769
  • [33] THE TEMPORAL PROFILES IN SERUM CONCENTRATIONS OF THE BIOMARKER S100B IN THE FIRST 48HOURS AFTER TRAUMATIC BRAIN INJURY CORRESPOND TO OUTCOME
    Thelin, Eric
    Johannesson, Louise
    Bellander, Bo-Michael
    JOURNAL OF NEUROTRAUMA, 2011, 28 (05) : A20 - A20
  • [34] ELEVATED SERUM PROTEIN S100B AND NEURON SPECIFIC ENOLASE VALUES AS PREDICTORS OF EARLY NEUROLOGICAL OUTCOME AFTER TRAUMATIC BRAIN INJURY
    Stefanovic, Branislava
    Duric, Olivera
    Stankovic, Sanja
    Mijatovic, Srdan
    Doklestic, Krstina
    Stefanovic, Branislav
    Jovanovic, Bojan
    Marjanovic, Natasa
    Kalezic, Nevena
    JOURNAL OF MEDICAL BIOCHEMISTRY, 2017, 36 (04) : 314 - 321
  • [35] S100B in brain damage and neurodegeneration
    Rothermundt, M
    Peters, M
    Prehn, JHM
    Arolt, V
    MICROSCOPY RESEARCH AND TECHNIQUE, 2003, 60 (06) : 614 - 632
  • [36] Secondary Peaks of S100B in Serum Relate to Subsequent Radiological Pathology in Traumatic Brain Injury
    Thelin, Eric P.
    Nelson, David W.
    Bellander, Bo-Michael
    NEUROCRITICAL CARE, 2014, 20 (02) : 217 - 229
  • [37] A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury
    Eric Peter Thelin
    David W. Nelson
    Bo-Michael Bellander
    Acta Neurochirurgica, 2017, 159 : 209 - 225
  • [38] A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury
    Thelin, Eric Peter
    Nelson, David W.
    Bellander, Bo-Michael
    ACTA NEUROCHIRURGICA, 2017, 159 (02) : 209 - 225
  • [39] Secondary Peaks of S100B in Serum Relate to Subsequent Radiological Pathology in Traumatic Brain Injury
    Eric P. Thelin
    David W. Nelson
    Bo-Michael Bellander
    Neurocritical Care, 2014, 20 : 217 - 229
  • [40] Serial measurement of S100B and NSE in pediatric traumatic brain injury
    Dae-Won Park
    Seong-Hyun Park
    Sung-Kyoo Hwang
    Child's Nervous System, 2019, 35 : 343 - 348